[go: up one dir, main page]

NO20021433D0 - vaccinations - Google Patents

vaccinations

Info

Publication number
NO20021433D0
NO20021433D0 NO20021433A NO20021433A NO20021433D0 NO 20021433 D0 NO20021433 D0 NO 20021433D0 NO 20021433 A NO20021433 A NO 20021433A NO 20021433 A NO20021433 A NO 20021433A NO 20021433 D0 NO20021433 D0 NO 20021433D0
Authority
NO
Norway
Prior art keywords
vaccinations
Prior art date
Application number
NO20021433A
Other languages
Norwegian (no)
Other versions
NO20021433L (en
Inventor
Martin Friede
Philippe Hermand
Veronique Henerickx
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9922703.5A external-priority patent/GB9922703D0/en
Priority claimed from GB0016685A external-priority patent/GB0016685D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of NO20021433D0 publication Critical patent/NO20021433D0/en
Publication of NO20021433L publication Critical patent/NO20021433L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NO20021433A 1999-09-24 2002-03-21 vaccinations NO20021433L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9922703.5A GB9922703D0 (en) 1999-09-24 1999-09-24 Vaccine
GB0016685A GB0016685D0 (en) 2000-07-06 2000-07-06 Novel compounds
PCT/EP2000/009366 WO2001021207A2 (en) 1999-09-24 2000-09-22 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines

Publications (2)

Publication Number Publication Date
NO20021433D0 true NO20021433D0 (en) 2002-03-21
NO20021433L NO20021433L (en) 2002-05-21

Family

ID=26244613

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021433A NO20021433L (en) 1999-09-24 2002-03-21 vaccinations

Country Status (17)

Country Link
EP (1) EP1221971A2 (en)
JP (1) JP2003509473A (en)
KR (1) KR20020038770A (en)
CN (1) CN1391483A (en)
AU (1) AU765824B2 (en)
BR (1) BR0014282A (en)
CA (1) CA2383413A1 (en)
CO (1) CO5200837A1 (en)
CZ (1) CZ20021043A3 (en)
HK (1) HK1049106A1 (en)
HU (1) HUP0202885A3 (en)
IL (1) IL148672A0 (en)
MX (1) MXPA02003067A (en)
NO (1) NO20021433L (en)
PL (1) PL355163A1 (en)
TR (1) TR200200774T2 (en)
WO (1) WO2001021207A2 (en)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737413T2 (en) 1996-01-04 2007-10-31 Novartis Vaccines and Diagnostics, Inc., Emeryville BACTERIOFERRITINE FROM HELICOBACTER PYLORI
NZ560966A (en) 2000-10-27 2010-06-25 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
JP2004535765A (en) 2000-12-07 2004-12-02 カイロン コーポレイション Endogenous retrovirus up-regulated in prostate cancer
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
US7501134B2 (en) 2002-02-20 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
ATE545651T1 (en) 2002-06-13 2012-03-15 Novartis Vaccines & Diagnostic VECTORS FOR EXPRESSING HML-2 POLYPEPTIDES
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP1549338B1 (en) 2002-10-11 2010-12-22 Novartis Vaccines and Diagnostics S.r.l. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
DK2279746T3 (en) 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic SURFACE PROTEINS IN NEISSERIA MENINGITIDIS
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
JP2006520746A (en) 2002-12-27 2006-09-14 カイロン コーポレイション Immunogenic compositions comprising phospholipids
ES2383175T3 (en) 2003-01-30 2012-06-18 Novartis Ag Injectable vaccines against multiple serogroups of meningococci
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2004092360A2 (en) 2003-04-10 2004-10-28 Chiron Corporation The severe acute respiratory syndrome coronavirus
US9107831B2 (en) 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
PL1670506T3 (en) 2003-10-02 2013-04-30 Novartis Ag Liquid vaccines for multiple meningococcal serogroups
JP5600375B2 (en) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Influenza virus vaccine
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
WO2005105140A2 (en) 2004-04-30 2005-11-10 Chiron Srl Meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP1784211A4 (en) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (en) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
WO2006091517A2 (en) 2005-02-18 2006-08-31 Novartis Vaccines And Diagnostics Inc. Immunogens from uropathogenic escherichia coli
SG160329A1 (en) 2005-02-18 2010-04-29 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
WO2007015441A1 (en) 2005-08-01 2007-02-08 Hisamitsu Pharmaceutical Co., Inc. Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2006310336B2 (en) 2005-11-04 2011-02-03 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ567980A (en) * 2005-11-04 2012-01-12 Novartis Vaccines & Diagnostic Administration routes (intranasal or mucosal and parenteral or intramuscular) for priming/boosting with influenza vaccines
JP5215865B2 (en) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
JP6087041B2 (en) 2006-01-27 2017-03-08 ノバルティス アーゲー Influenza virus vaccine containing hemagglutinin and matrix protein
US8535683B2 (en) 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
ES2376492T3 (en) 2006-03-23 2012-03-14 Novartis Ag IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS.
CA2646349A1 (en) * 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
ATE522541T1 (en) 2006-06-09 2011-09-15 Novartis Ag BACTERIAL ADHESIN CONFORMERS
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
EA200970271A1 (en) 2006-09-11 2010-02-26 Новартис Аг OBTAINING VACCINES AGAINST THE VIRUS OF THE INFLUENZA WITHOUT USING THE CHICKEN EMBRYOS
AU2007330494B2 (en) 2006-12-06 2014-03-13 Seqirus UK Limited Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2123296B1 (en) * 2007-01-31 2019-05-22 Hisamitsu Pharmaceutical Co., Inc. Adjuvant for transdermal or transmucosal administration and pharmaceutical preparation containing the same
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8815253B2 (en) 2007-12-07 2014-08-26 Novartis Ag Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2537857B1 (en) 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutant forms of streptolysin O
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
EP2631245A1 (en) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
WO2010092479A2 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with reduced amounts of squalene
EP3549602A1 (en) 2009-03-06 2019-10-09 GlaxoSmithKline Biologicals S.A. Chlamydia antigens
CA2758490C (en) 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
ES2552153T3 (en) 2009-04-30 2015-11-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
CN102802665B (en) 2009-06-15 2015-11-25 新加坡国立大学 Influenza vaccines, compositions and methods of use
MX2012000395A (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens.
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
MX2012000734A (en) 2009-07-16 2012-01-27 Novartis Ag Detoxified escherichia coli immunogens.
RU2518291C2 (en) 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Antigen tau-peptides and their application
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
PE20161560A1 (en) 2009-09-03 2017-01-11 Pfizer Vaccines Llc PCSK9 VACCINE
RU2603267C2 (en) 2009-09-30 2016-11-27 Новартис Аг Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
CN102917730A (en) 2009-10-27 2013-02-06 诺华有限公司 Modified meningococcal fHBP polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
KR20120120185A (en) 2009-12-22 2012-11-01 셀덱스 쎄라퓨틱스, 인크. Vaccine compositions
JP5781542B2 (en) 2009-12-30 2015-09-24 ノバルティス アーゲー E. polysaccharide immunogen conjugated to an E. coli carrier protein
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
EP3327028B1 (en) 2010-03-30 2022-03-16 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
US9597326B2 (en) 2010-04-13 2017-03-21 Glaxosmithkline Biologicals Sa Benzonapthyridine compositions and uses thereof
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2576613A1 (en) 2010-06-07 2013-04-10 Pfizer Inc. Her-2 peptides and vaccines
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
MX2013000163A (en) 2010-07-06 2013-03-05 Novartis Ag Norovirus derived immunogenic compositions and methods.
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
ES3018416T3 (en) 2011-01-26 2025-05-16 Glaxosmithkline Biologicals Sa RSV immunization regimen
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
PL2707385T3 (en) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fusion rsv f antigens
JP2014520807A (en) 2011-07-06 2014-08-25 ノバルティス アーゲー Immunogenic compositions and uses thereof
ES2656050T3 (en) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
EP2736921B1 (en) 2011-07-25 2018-06-27 GlaxoSmithKline Biologicals SA Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
SG11201407440WA (en) 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
CN105307684A (en) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 Nonlinear saccharide conjugates
KR20150073943A (en) 2012-10-03 2015-07-01 글락소스미스클라인 바이오로지칼즈 에스.에이. Immunogenic composition
EP2925355B1 (en) 2012-11-30 2017-11-15 GlaxoSmithKline Biologicals S.A. Pseudomonas antigens and antigen combinations
CN105263517B (en) 2013-05-15 2021-03-26 阿尔伯达大学董事会 E1E2HCV vaccine and method of use
WO2015064710A1 (en) 2013-10-31 2015-05-07 久光製薬株式会社 Adjuvant composition, adjuvant preparation containing same, and kit
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN110859957B (en) 2014-01-21 2024-04-12 辉瑞公司 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
CN106715464B (en) 2014-07-23 2021-03-16 奥克兰儿童医院及研究中心 Factor H binding protein variants and methods of use
PL3244917T3 (en) 2015-01-15 2023-07-17 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP3302536A1 (en) 2015-06-03 2018-04-11 Affiris AG Il-23-p19 vaccines
CA2991544A1 (en) 2015-07-07 2017-01-12 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
KR20210027523A (en) 2015-07-21 2021-03-10 화이자 인코포레이티드 Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP4480544A3 (en) 2015-08-25 2025-03-26 Babita Agrawal Immunomodulatory compositions andmethods of use thereof
CN108290960B (en) 2015-10-08 2023-06-09 艾伯塔大学理事会 Hepatitis C virus E1/E2 heterodimer and production method thereof
JP6884145B2 (en) 2015-11-20 2021-06-09 ファイザー・インク Immunogenic composition for use in Streptococcus pneumoniae vaccine
ES2811523T3 (en) 2016-01-19 2021-03-12 Pfizer Cancer vaccines
AU2018208844B2 (en) 2017-01-20 2021-02-25 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2018449744A1 (en) 2018-11-16 2021-05-27 Versitech Limited Live attenuated influenza B virus compositions methods of making and using thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
BR112022014555A2 (en) 2020-02-23 2022-09-20 Pfizer COMPOSITIONS OF ESCHERICHIA COLI AND METHODS THEREOF.
JP2023514825A (en) 2020-02-26 2023-04-11 ヴェルシテック リミテッド PD-1-based vaccine against coronavirus infection
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022090893A2 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
CN116744965A (en) 2020-11-04 2023-09-12 辉瑞大药厂 Immunogenic compositions for pneumococcal vaccines
EP4243863A2 (en) 2020-11-10 2023-09-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TWI750929B (en) * 2020-12-02 2021-12-21 林建宏 Temperature-sensitive adjuvant for aerosol immunity and its preparation method
CA3201103C (en) * 2020-12-18 2023-12-12 Simon BEAUDOIN Covalently modified antigens for improved immune response and/or stability
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US20240299510A1 (en) 2020-12-31 2024-09-12 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
TW202245836A (en) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 Meningococcal b recombinant vaccine
EP4333868A1 (en) 2021-05-04 2024-03-13 King Abdullah University Of Science And Technology Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
AU2022281543A1 (en) 2021-05-28 2023-11-23 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202306969A (en) 2021-05-28 2023-02-16 美商輝瑞大藥廠 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
WO2023079529A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Re-focusing protein booster immunization compositions and methods of use thereof
AU2022391752A1 (en) 2021-11-18 2024-06-13 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
EP4522208A1 (en) 2022-05-11 2025-03-19 Pfizer Inc. Process for producing of vaccine formulations with preservatives
AU2023309805A1 (en) 2022-07-22 2025-01-23 Centre Hospitalier Universitaire De Lille Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
KR20250107930A (en) 2022-11-22 2025-07-14 화이자 인코포레이티드 Immunogenic composition comprising conjugated membrane saccharide antigen and use thereof
EP4626405A1 (en) 2022-12-01 2025-10-08 Pfizer Inc. Pneumococcal conjugate vaccine formulations
EP4633671A1 (en) 2022-12-14 2025-10-22 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
NL8403195A (en) * 1984-10-19 1986-05-16 Nederlanden Staat IMMUNOGENIC COMPLEXES AND VACCINES CONTAINING THESE.
CA1291036C (en) * 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals

Also Published As

Publication number Publication date
WO2001021207A2 (en) 2001-03-29
HK1049106A1 (en) 2003-05-02
JP2003509473A (en) 2003-03-11
EP1221971A2 (en) 2002-07-17
KR20020038770A (en) 2002-05-23
WO2001021207A3 (en) 2001-09-27
NO20021433L (en) 2002-05-21
CZ20021043A3 (en) 2002-08-14
AU7907000A (en) 2001-04-24
AU765824B2 (en) 2003-10-02
PL355163A1 (en) 2004-04-05
TR200200774T2 (en) 2002-08-21
IL148672A0 (en) 2002-09-12
HUP0202885A3 (en) 2004-07-28
CO5200837A1 (en) 2002-09-27
CA2383413A1 (en) 2001-03-29
BR0014282A (en) 2002-05-21
MXPA02003067A (en) 2002-09-30
HUP0202885A2 (en) 2002-12-28
CN1391483A (en) 2003-01-15

Similar Documents

Publication Publication Date Title
NO20021433L (en) vaccinations
NO20014323L (en) Vaccine
NO20030823L (en) vaccinations
NO20031705D0 (en) vaccinations
ID26056A (en) DIAPON ONCE USE
DE122007000064I1 (en) Erythropoietinkonjugate
ID26389A (en) DIAPON ONCE USE
DE19983871T1 (en) Fönvorrichtung
DE50002834D1 (en) handstamp
ATE357433T1 (en) 4-PYRIMIDINYL-N-ACYL-L-PHENYLANINE
DE60002650D1 (en) Oil-vaccinated vaccine
NO20020763L (en) Vaccine
ATE297895T1 (en) 4-PYRIDINYL-N-ACYL-L-PHENYLALANINE
ID25571A (en) DIAPON ONCE USE
ID24782A (en) DIAPON ONCE USE
DE60022878D1 (en) KONZENTRIZITÄTSRING
ID27526A (en) TURUNAN II KUINOLIN-4-IL
DE50000805D1 (en) Aufsitzspanner
DE10085008T1 (en) Oberflächenbehandlungsdüse
DE19983890T1 (en) Ventiltaktgebungsjustiereinrichtung
DE50001640D1 (en) NAHFELDOPTISCHE INTERSUCHUNGSVORRICHTUNG
ATE440824T1 (en) NITRO-SULFOBENSAMIDE
ATE269311T1 (en) BENZOYLPYRIDAZINE
ATA121799A (en) AUSBEULGERÄT
ATA107599A (en) HEIZWASSERBEREITER

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application